Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors generally and empagliflozin specifically
have shown cardiovascular benefits in patients with heart failure (HF), but the underlying
mechanisms remain unclear. Empagliflozin use resulted in lower pulmonary artery diastolic
pressures in patients with HF, suggesting a beneficial diuretic effect. Other potential
mechanisms include increased blood volume, decreased blood pressure, and changes in
sympathetic and neuro-hormonal activation.
This study is a single-arm, open label, prospective interventional study of 8 subjects with
heart failure with preserved ejection fraction (HFpEF) and diabetes. Before and after 12
weeks of daily empagliflozin, participants with undergo comprehensive invasive exercise
testing with a right heart catheter. Our goal is to evaluate the effects of empagliflozin on
fitness, assessed by peak VO2, and peak left ventricular filling pressure, assessed by
pulmonary capillary pressure at peak exercise.